Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.55 |
| ▸ | ADA | P00813 | 5/20 | 0.48 |
| ▸ | PDE2A | O00408 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | AHCY | P23526 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6534224 | 0.84 | EHMT1 (0.48) | EHMT1AHCYPOLBENPP1P2RY1 | |
| SCHEMBL6534166 | 0.84 | AHCY (0.48) | EHMT1AHCYPOLBENPP1P2RY1 | |
| SCHEMBL66046 | 0.83 | AHCY (0.57) | ADAALDH1A1HSD17B10BLMAHCY | |
| SCHEMBL28121858 | 0.82 | AHCY (0.56) | ADAALDH1A1HSD17B10BLMAHCY | |
| SCHEMBL4451661 | 0.82 | AHCY (0.59) | ADAALDH1A1HSD17B10BLMAHCY | |
| SCHEMBL29375190 | 0.81 | AHCY (0.55) | ADAALDH1A1HSD17B10BLMAHCY | |
| SCHEMBL2505364 | 0.81 | AHCY (0.55) | ADAALDH1A1HSD17B10BLMAHCY | |
| SCHEMBL29739820 | 0.81 | AHCY (0.55) | ADAALDH1A1HSD17B10BLMAHCY | |
| SCHEMBL28939795 | 0.81 | AHCY (0.55) | ADAALDH1A1HSD17B10BLMAHCY | |
| SCHEMBL16174350 | 0.81 | EHMT1 (0.51) | EHMT1HIF1APOLBENPP1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192635-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-09-30 | — | — | US | disclosed |
| US-6743782-B1 | ACYL DERIVATIVE OF 2'-DEOXYADENOSINE; TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED CELLULAR DAMAGE, IMPROVING WOUND HEALING AND TISSUE REPAIR, AMELIORATING THE EFFECTS OF AGING; ENHANCE BIOAVAILABILITY | WELLSTAT THERAPEUTICS CORPORATION | 2004-06-01 | — | — | US | disclosed |
| EP-0712629-B1 | Acyl deoxyribonucleoside derivatives and uses thereof | WELLSTAT THERAPEUTICS CORP (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6348451-B1 | WOUND HEALING AGENTS FOR ANIMALS | PRO-NEURON, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6306834-B1 | METHODS OF TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED BIOLOGICAL DAMAGE, METHODS FOR IMPROVING WOUND HEALING AND TISSUE REPAIR, COMPRISING ADMINISTERING THE COMPOSITIONS OF THE PRESENT INVENTION TO AN ANIMAL. | PRO-NEURON, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6297222-B1 | TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED BIOLOGICAL DAMAGE, AND METHODS FOR IMPROVING WOUND HEALING AND TISSUE REPAIR | PRO-NEURON, INC. | 2001-10-02 | — | — | US | disclosed |
| US-6103701-A | ADMINISTERING COMPOSITIONS COMPRISING ACYL DERIVATIVES OF 2'-DEOXYRIBONUCLEOSIDES; FOR IMPROVING WOUND HEALING AND TISSUE REPAIR | VON BORSTEL REID WARREN (US) | 2000-08-15 | — | — | US | disclosed |
| US-6020322-A | Acyl deoxyribonucleoside derivatives and uses thereof | PRO-NEURON, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| US-6020320-A | Acyl deoxyribonucleoside derivatives and uses thereof | PRO-NEURON, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0355131-B1 | ACYL DEOXYRIBONUCLEOSIDE DERIVATIVES AND USES THEREOF | PRO NEURON INC (US) | 1996-09-04 | — | — | EP | disclosed |
| EP-0712629-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | PRO-NEURON, INC. (US) | 1996-05-22 | — | — | EP | disclosed |
| EP-0355131-A1 | ACYL DEOXYRIBONUCLEOSIDE DERIVATIVES AND USES THEREOF | PRO-NEURON, INC. (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192635-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | UNG, OGG1, NQO1 | EHMT1 1638/4885ADA 61/4885PDE2A 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.